Navitoclax improves acute-on-chronic liver failure by eliminating senescent cells in mice.

Yusuke WatanabeHiroyuki AbeNaruhiro KimuraYoshihisa AraoNatsuki IshikawaMaeda YuichiroToru SetsuAkira SakamakiHiroteru KamimuraTakeshi YokooKenya KamimuraAtsunori TsuchiyaShuji Terai

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)

Navi may ameliorate ACLF damage by eliminating senescent cells in the liver, downregulating SASP factors, and upregulating mitochondrial functions. We believe that this novel approach using Navi will pave the way for ACLF treatment. This article is protected by copyright. All rights reserved.

Keyphrases

liver failure
induced apoptosis
cell cycle arrest
hepatitis b virus
oxidative stress
endoplasmic reticulum stress
type diabetes
metabolic syndrome
drug induced
intensive care unit
skeletal muscle
combination therapy